公开(公告)号：US12129310B2

公开(公告)日：2024-10-29

申请号：US18122948

申请日：2023-03-17

Applicant: Janssen Biotech, Inc.

Inventor： Sanjaya Singh ,  Rajkumar Ganesan ,  Jun Chen ,  Iqbal S. Grewal

IPC: C07K16/42 ,  G01N33/68

CPC classification number: C07K16/42 ,  G01N33/6857 ,  C07K2317/14 ,  C07K2317/34

Abstract: Molecules, including antibodies and antigen-binding fragments thereof that specifically bind to a linker peptide, and methods of producing and using the described antibodies and antigen-binding fragments are presented herein. Also presented herein methods of generating antibodies that specifically bind to an immunorecessive epitope.

公开(公告)号：US20240317839A1

公开(公告)日：2024-09-26

申请号：US18436355

申请日：2024-02-08

Applicant: Avacta Life Sciences Limited

Inventor： Geoffrey William Platt ,  Graham Robert Pye-Smith Spence

IPC: C07K14/81 ,  C07K16/28 ,  C07K16/32 ,  C07K16/42

CPC classification number: C07K14/8139 ,  C07K16/2827 ,  C07K16/32 ,  C07K16/42 ,  C07K2318/20 ,  C07K2319/30 ,  C07K2319/31

Abstract: The invention relates to a polypeptide, such as an Affimer polypeptide, comprising an amino acid sequence having at least 80% identity to amino acid residues 1 to 11, 13 to 15, 17 to 19, 21 to 25, 27 to 28, 35 to 37, 39, 41, 43 to 44, 46 to 47, 49 to 50, 52 to 53, 55 to 58, 63 to 64, 66, 68 to 82, 84 to 85, and 87 to 98 of SEQ ID NO: 1; characterized in that said polypeptide comprises one or mutations relative to SEQ ID NO: 1. The invention also relates to various methods and nucleic acids.

公开(公告)号：US20240132624A1

公开(公告)日：2024-04-25

申请号：US18360393

申请日：2023-07-27

Applicant: Ablynx N.V. ,  Sanofi

Inventor： Tom Van Bogaert ,  Judith Verhelst ,  Stephanie Staelens ,  Carlo Boutton ,  Wilbert De Witte ,  Thomas Bertrand

IPC: C07K16/42 ,  A61K47/68 ,  C07K16/18

CPC classification number: C07K16/42 ,  A61K47/6873 ,  C07K16/18 ,  C07K2317/31 ,  C07K2317/569

Abstract: The present invention relates to polypeptides that are capable of binding to a specific epitope on the neonatal Fc receptor (FcRn). In particular, the present invention relates to novel and improved polypeptides comprising immunoglobulin single variable domains (ISVDs), such as heavy-chain single variable domains, that are capable of binding to a specific epitope on FcRn. The invention further relates to constructs, compounds, molecules or chemical entities that comprise at least one of these ISVDs binding to a specific epitope on FcRn. The present invention further relates to methods for producing such polypeptides as well as to uses of such polypeptides for diverse applications, including but not limited to the extension of the half-life in vivo of therapeutic compounds and/or the prevention and/or treatment of a disease and/or disorder, such as but not limited to a proliferative disease, an inflammatory disease, an infectious disease or an autoimmune disease.

公开(公告)号：US20230293635A1

公开(公告)日：2023-09-21

申请号：US18156016

申请日：2023-01-18

Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER ,  EVIVE BIOTECHNOLOGY (SHANGHAI) LTD

Inventor： Marcel VAN DEN BRINK ,  Alan HANASH ,  Caroline LINDEMANS ,  Tom TANG

IPC: A61K38/20 ,  C07K14/54

CPC classification number: A61K38/20 ,  C07K14/54 ,  C07K16/42

Abstract: The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.

公开(公告)号：US20230212316A1

公开(公告)日：2023-07-06

申请号：US18079188

申请日：2022-12-12

Applicant: Wisconsin Alumni Research Foundation

Inventor： Miriam Shelef

IPC: C07K16/42 ,  G01N33/564 ,  A61K45/06 ,  A61P31/14 ,  A61P19/02

CPC classification number: C07K16/42 ,  G01N33/564 ,  A61K45/06 ,  A61P31/14 ,  A61P19/02

Abstract: Described herein are IgG epitope peptides that bind rheumatoid factors in rheumatoid arthritis (RA) and COVID-19. The IgG epitope peptides may be conjugated to a ligand, a detectable label, or a combination thereof. Also, the IgG epitope peptides are particularly useful in assays to detect antibodies in blood samples from subjects with RA risk factors, for example. The COVID-19 IgG epitope peptides are particularly useful in screening convalescent plasma.

公开(公告)号：US20230203189A1

公开(公告)日：2023-06-29

申请号：US18168930

申请日：2023-02-14

Applicant: MORPHOSYS AG

Inventor： Stefan Härtle

IPC: C07K16/30 ,  C07K16/42 ,  G01N33/574 ,  A61P35/00 ,  C07K14/76 ,  G01N33/49 ,  G01N33/561

CPC classification number: C07K16/30 ,  C07K16/42 ,  G01N33/57426 ,  A61P35/00 ,  C07K14/76 ,  G01N33/49 ,  G01N33/561 ,  C07K2317/565 ,  C07K2317/56 ,  C07K2319/31 ,  G01N2800/52

Abstract: Applicant discloses an anti-idiotypic antibody to MOR202, which when fused to human albumin, shifted the antibody in IFE thus mitigating any potential interference of MOR202 with the M-protein clinical assessment.

公开(公告)号：US11673930B2

公开(公告)日：2023-06-13

申请号：US17317475

申请日：2021-05-11

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jie Dai ,  Maria del Pilar Molina-Portela ,  Ella Ioffe ,  Markus Mohrs

IPC: A61K38/20 ,  A61K47/68 ,  C07K14/54 ,  C07K19/00 ,  A61P35/00 ,  C07K1/22 ,  C07K16/42 ,  A61K38/00

CPC classification number: C07K14/5428 ,  A61K38/2066 ,  A61K47/68 ,  A61K47/6889 ,  A61P35/00 ,  C07K1/22 ,  C07K16/42 ,  A61K38/00 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2319/30

Abstract: The present disclosure relates to IL10 agonists with improved anti-tumor therapeutic efficacy. IL10 agonists disclosed herein comprise an IgG Fc domain, a linker moiety, and an IL10 moiety.

公开(公告)号：US11649295B2

公开(公告)日：2023-05-16

申请号：US16599883

申请日：2019-10-11

Applicant: argenx BV

Inventor： Christophe Frederic Jerome Blanchetot ,  Johannes Joseph Wilhelmus De Haard

IPC: C07K16/46 ,  C07K16/42 ,  C07K1/22

CPC classification number: C07K16/468 ,  C07K1/22 ,  C07K16/42 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/569 ,  C07K2317/64

Abstract: The present invention relates to multispecific antibodies, for example bispecific antibodies, and methods for the isolation or purification of the same. The antibodies of the invention comprise first and second heavy chain-light chain pairings wherein each pairing comprises a distinct selective recognition site including one or more amino acid residues contributed from the heavy chain and the light chain of the pairing. The first and second selective recognition sites differ by at least one amino acid residue and can be differentially bound by first and second selective recognition agents according to the methods of the invention. Such methods facilitate the production of antibody preparations enriched for multispecific antibodies having the correct functional heavy chain-light chain pairings.

公开(公告)号：US10041954B2

公开(公告)日：2018-08-07

申请号：US14891301

申请日：2014-03-18

Applicant: RESVO Inc.

Inventor： Arata Ohnishi ,  Takafumi Minamimoto ,  Tetsuya Suhara

IPC: G01N33/53 ,  G01N33/567 ,  G01N33/68 ,  C07K16/42

CPC classification number: G01N33/6857 ,  C07K16/42 ,  G01N33/6863 ,  G01N33/6869 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2333/525 ,  G01N2333/5412 ,  G01N2333/545 ,  G01N2800/2821 ,  G01N2800/301 ,  G01N2800/302 ,  G01N2800/304

Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free κ immunoglobulin chains, free λ immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects. The biomarker enables more effective tests and diagnoses to be conducted combining inflammatory cytokines in the blood of patients with psychiatric and neurological disorders.

公开(公告)号：US20180169240A1

公开(公告)日：2018-06-21

申请号：US15739622

申请日：2016-06-23

Applicant: Graham PARRY ,  Pavel A. NIKITIN ,  TRUE NORTH THERAPEUTICS, INC.

Inventor： Graham PARRY ,  Pavel A. NIKITIN ,  Sandip PANICKER

IPC: A61K39/395 ,  C07K16/40 ,  C07K16/42 ,  A61K35/15

CPC classification number: A61K39/39566 ,  A61K35/15 ,  A61K39/395 ,  A61K39/39541 ,  A61K2039/505 ,  C07K16/40 ,  C07K16/42 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76

Abstract: The present disclosure provides methods of treating an alloimmune or autoimmune disorder in an individual; the methods involve administering to the individual an effective amount of an antibody specific for complement component C1s. The present disclosure provides a method of monitoring the efficacy of a subject treatment method; the method involves detecting the level of autoantibody or alloantibody in a biological sample obtained from the individual.